Company intelligence / Profile preview

One-carbon Therapeutics AB

Solna, Stockholm County, Swedenone-carbon.com ↗

Ownership: Private
Development stage: Preclinical

Overview

One-carbon Therapeutics AB is developing first-in-class small molecule inhibitors of MTHFD1/2, with their lead candidate TH9619 showing strong efficacy in multiple cancer models. The company is preparing regulatory submissions in 2024 and aims to start clinical Phase I trials in 2025. Their approach leverages deep expertise in DNA damage response biology, building on discoveries from the Helleday Laboratory at Karolinska Institute.

Therapeutic areas: OncologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

MTHFD1/2i

Pre-clinical

Indications: Cancer

Beyond the preview

Go deeper on One-carbon Therapeutics AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on One-carbon Therapeutics AB.

Explore the full profile